Your browser doesn't support javascript.
loading
Effectiveness of a Second Dose of an mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in Individuals Previously Infected by Other Variants.
Monge, Susana; Rojas-Benedicto, Ayelén; Olmedo, Carmen; Martín-Merino, Elisa; Mazagatos, Clara; Limia, Aurora; Sierra, María José; Larrauri, Amparo; Hernán, Miguel A.
Afiliación
  • Monge S; Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • Rojas-Benedicto A; CIBER on Infectious Diseases, Madrid, Spain.
  • Olmedo C; Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • Martín-Merino E; CIBER on Epidemiology and Public Health, Madrid, Spain.
  • Mazagatos C; National Distance Education University, Madrid, Spain.
  • Limia A; Vaccines Division, General Directorate of Public Health, Ministry of Health, Madrid, Spain.
  • Sierra MJ; Spanish Agency of Medicines and Medical Devices (AEMPS), Madrid, Spain.
  • Larrauri A; Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • Hernán MA; CIBER on Epidemiology and Public Health, Madrid, Spain.
Clin Infect Dis ; 76(3): e367-e374, 2023 02 08.
Article en En | MEDLINE | ID: mdl-35687580
BACKGROUND: Single-dose vaccination was widely recommended in the pre-Omicron era for persons with previous SARS-CoV-2 infection. The effectiveness of a second vaccine dose in this group in the Omicron era is unknown. METHODS: We linked nationwide population registries in Spain to identify community-dwelling individuals aged 18-64, with a positive SARS-CoV-2 test before single-dose mRNA vaccination (mRNA-1273 or BNT162b2). Every day between 3 January and 6 February 2022 we matched 1:1 individuals receiving a second mRNA vaccine dose and controls on sex, age, province, first dose type and time, month of primary infection, and number of previous tests. We then estimated Kaplan-Meier risks of confirmed SARS-CoV-2 reinfection. We performed a similar analysis in a Delta-dominant period, between 19 July and 30 November 2021. RESULTS: In the Omicron period, estimated effectiveness (95% CI) of a second dose was 62.2% (58.2-66.4%) 7-34 days after administration, similar across groups defined by age, sex, type of first vaccine, and time since the first dose. Estimated effectiveness was 65.4% (61.1-69.9%) for mRNA-1273 and 52.0% (41.8-63.1%) for BNT162b2. Estimated effectiveness was 78.5% (67.4-89.9%), 66.1% (54.9-77.5%), and 60.2% (55.5-64.8%) when primary infection had occurred in the Delta, Alpha, and pre-Alpha periods, respectively. In the Delta period, the estimated effectiveness of a second dose was 8.8% (-55.3% to 81.1%). CONCLUSIONS: Our results suggest that, over 1 month after administration, a second dose of mRNA vaccine increases protection against SARS-CoV-2 reinfection with the Omicron variant among individuals with single-dose vaccination and previously infected with another variant.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos